Werewolf Therapeutics

Werewolf Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Werewolf Therapeutics (HOWL) as of Oct 30, 2026 is 99.13 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 80.04 % — a change of 23.84% (higher).

FCF Conversion

99.13 %

YoY

23.84%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Werewolf Therapeutics is 2025 99.13 % . FCF Conversion Rate (FCF/EBITDA) of Werewolf Therapeutics was 2024 80.04 % . It decreases by 23.84% higher compared to the previous year.

The Werewolf Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
89.24 USD
Jan 1, 2020
128.42 USD
Jan 1, 2021
87.15 USD
Jan 1, 2022
85.73 USD
Jan 1, 2023
89.33 USD
Jan 1, 2024
80.04 USD
Jan 1, 2025
99.13 USD
The Werewolf Therapeutics FCF Conversion history
YEARFCF ConversionYoY
99.13 %+23.84%
80.04 %-10.40%
89.33 %+4.20%
85.73 %-1.63%
87.15 %-32.13%
128.42 %+43.89%
89.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Werewolf Therapeutics Stock analysis

What does Werewolf Therapeutics do? Werewolf Therapeutics Inc, based in Watertown, Massachusetts, is a biopharmaceutical company operating in the Health Care sector. The company focuses on developing therapeutics that stimulate the immune system to treat cancer, utilizing its PREDATOR platform to create conditionally activated molecules. With 46 employees, it is advancing clinical-stage candidates WTX-124 and WTX-330, systemically delivered IL-2 and IL-12 INDUKINE molecules designed to selectively activate in the tumor microenvironment for solid tumor treatment. Werewolf Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Werewolf Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of Werewolf Therapeutics is 99.13 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Werewolf Therapeutics changed from 80.04 % to 99.13 %, representing a 23.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Werewolf Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Werewolf Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Werewolf Therapeutics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Werewolf Therapeutics